The Effectiveness of an Occupation-Based Lifestyle Program in Individuals With Type 2 Diabetes
This study aims to investigate the effect of an occupation-focused lifestyle program on occupational performance, self-management, occupational balance, diabetes symptoms, and quality of life in individuals with Type 2 diabetes.
Type 2 diabetes requires continuous daily management, yet conventional interventions often show limited long-term behavioral sustainability. Occupation-focused lifestyle interventions offer a holistic approach by addressing daily routines, self-management skills, and personal goals.
In this non-invasive, quasi-experimental study, participants aged 18-74 with Type 2 diabetes will be invited via social media announcements. Participants will be divided into an intervention group and a control group. The intervention group will receive an online, 5-module (8 sessions) Occupation-Focused Lifestyle Program via Zoom, covering diabetes awareness, problem-solving, stress management (mindfulness), energy conservation/physical activity, and goal review. The control group will receive an informative brochure after the intervention group completes the program. Outcomes will be measured online before and after the program using structured scales to evaluate changes in daily functioning, self-care, and overall well-being
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Background and Rationale:
Type 2 diabetes mellitus accounts for 90-95% of diabetes cases worldwide and presents significant challenges in physical and psychosocial functioning. Effective management requires long-term lifestyle adaptations, including healthy eating, physical activity, blood glucose monitoring, medication adherence, problem-solving, and stress management. While traditional lifestyle interventions improve clinical indicators in the short term, their long-term behavioral sustainability can be limited. Occupation-focused occupational therapy interventions integrate diabetes self-management into daily habits and meaningful roles, offering a structured framework to improve quality of life and health outcomes.
Study Design and Population:
This study is a quasi-experimental controlled trial conducted online. The target population consists of individuals aged 18-74 who have been diagnosed with Type 2 diabetes for more than 12 months, have internet access for online sessions, and provide documented proof of their diagnosis. Sample size calculation using G*Power (alpha = 0.05, power = 0.80, effect size d = 0.8) determined a required total sample size of 42 participants (21 per group).
Intervention:
Participants in the intervention group will participate in an 8-session (60 minutes per session, twice weekly) online program via Zoom, structured into 5 modules:
Module 1: Awareness (Session 1): Education on diabetes management, identifying daily challenges, and establishing individual occupational priorities using the Canadian Occupational Performance Measure (COPM).
Module 2: Problem Solving (Sessions 2 & 3): Teaching structured problem-solving steps tailored to diabetes self-management and personal goals.
Module 3: Stress Management (Sessions 4 & 5): Training in mindfulness techniques (breath awareness, body scan, sensory awareness) and integrating them into daily routines.
Module 4: Energy Conservation and Physical Activity (Sessions 6 & 7): Instruction on activity-role balance, energy conservation principles, and embedding safe physical activities (walking, home exercises) into daily life.
Module 5: Goal Review and Sustainability (Session 8): Re-evaluating COPM goals, addressing barriers, and developing sustainable long-term strategies.
Participants in the control group will receive an informative educational brochure (covering diabetes awareness, problem-solving, physical activity, mindfulness, and energy conservation) upon completion of the intervention group's program.
Outcome Measures:
Data will be collected via Google Forms at baseline (pre-test) and post-intervention (post-test) using the following instruments:
Demographic and Health Information Form
Canadian Occupational Performance Measure (COPM): Evaluates occupational performance and satisfaction.
Diabetes Self-Management Questionnaire (DSMQ / DÖYS): Assesses self-care activities associated with glycemic control.
Occupational Balance Questionnaire (OBQ11-T / ARDA11-T): Measures satisfaction with the balance of daily activities and roles.
Diabetes Symptom Checklist (DSC / DBKLÖ): Evaluates the presence and burden of physical and psychological diabetes symptoms.
Short Form-36 Health Survey (SF-36): Measures health-related quality of life across 8 domains.
Program Satisfaction Survey: Evaluates intervention group feedback on program content, applicability, and online delivery.
Statistical Analysis:
Data analysis will be performed using SPSS (Version 26.0). Descriptive statistics will summarize participant characteristics. Within-group pre-post changes and between-group differences will be analyzed using parametric tests (paired t-test, independent samples t-test) or non-parametric tests (Wilcoxon signed-rank test, Mann-Whitney U test) depending on normality distributions, with significance set at p < 0.05.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Sena Albay, Msc
- Puhelinnumero: +90 5062511706
- Sähköposti: sena.albay@ankaramedipol.edu.tr
Opiskelupaikat
-
-
-
Ankara, Turkki (Türkiye)
- Rekrytointi
- Ankara Medipol University
-
Ottaa yhteyttä:
- Ankara Medipol University Ankara Medipol University
- Sähköposti: info@ankaramedipol.edu.tr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Diagnosed with Type 2 Diabetes Mellitus for at least 12 months
- Aged between 18 and 74 years
- Ability to provide documented proof of Type 2 diabetes diagnosis (e.g., medical report or official documentation)
- Having access to a smartphone, tablet, or computer with an internet connection to attend online Zoom sessions and complete online questionnaires -Voluntary agreement to participate in the study and submission of an online informed consent form
Exclusion Criteria:
- Presence of severe diabetic complications that significantly impair independent daily function (e.g., severe proliferative retinopathy, end-stage renal disease, active foot ulcers, or severe diabetic neuropathy)
- Cognitive impairment, acute psychiatric conditions, or sensory deficits (uncorrected visual or hearing impairments) that impede active participation in group sessions or online communication
- Participation in another structured diabetes self-management program or lifestyle intervention trial simultaneously
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Intervention Group
Participants receive an online, 5-module (8 sessions, twice weekly, 60 minutes each via Zoom) Occupation-Focused Lifestyle Program. The program covers diabetes awareness, problem-solving, stress management (mindfulness), energy conservation/physical activity, and goal setting. |
An online, 5-module (8 sessions, 60 minutes each, twice weekly via Zoom) intervention led by occupational therapy staff. The program incorporates diabetes awareness, structured problem-solving, stress management (mindfulness), energy conservation, safe physical activity integration, and goal setting using the Canadian Occupational Performance Measure (COPM) |
|
Ei väliintuloa: Control Group
Participants maintain their routine care during the study period. After the intervention group completes the program and post-tests, the control group receives an informative educational brochure covering the program topics. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Canadian Occupational Performance Measure (COPM)
Aikaikkuna: Baseline (Week 0) and Post-intervention (Week 4)
|
Assesses individual occupational performance and satisfaction in self-care, productivity, and leisure domains. Scores range from 1 to 10 for both subscales, with higher scores indicating higher self-perceived performance and satisfaction. |
Baseline (Week 0) and Post-intervention (Week 4)
|
|
Diabetes Self-Management Questionnaire (DSMQ)
Aikaikkuna: Baseline (Week 0) and Post-intervention (Week 4)
|
Evaluates self-care behaviors related to glycemic control, where higher scores indicate better self-management practices. |
Baseline (Week 0) and Post-intervention (Week 4)
|
|
Occupational Balance Questionnaire (OBQ11)
Aikaikkuna: Baseline (Week 0) and Post-intervention (Week 4)
|
Measures satisfaction with the balance of daily activities and roles, with higher scores reflecting greater occupational balance. |
Baseline (Week 0) and Post-intervention (Week 4)
|
|
Diabetes Symptom Checklist-Revised (DSC-R)
Aikaikkuna: Baseline (Week 0) and Post-intervention (Week 4)
|
Evaluates the presence and perceived burden of diabetes-related physical and psychological symptoms. |
Baseline (Week 0) and Post-intervention (Week 4)
|
|
Short Form-36 Health Survey (SF-36)
Aikaikkuna: Baseline (Week 0) and Post-intervention (Week 4)
|
Measures health-related quality of life across physical and mental health domains, with higher scores reflecting better health status. |
Baseline (Week 0) and Post-intervention (Week 4)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 199
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
De-identified individual participant data collected during the trial will be available upon reasonable request from qualified researchers after publication of the primary study results. Requests should be directed to the principal investigator and require a methodologically sound proposal and a signed data access agreement to ensure participant confidentiality.
IPD-jaon aikakehys
Available upon reasonable request starting 6 months following the publication of the primary study results and ending 3 years after the publication date.
IPD-jaon käyttöoikeuskriteerit
Qualified academic researchers with a methodologically sound research proposal aimed at achieving the approved objectives will be granted access to de-identified individual participant data. Requesters must submit a formal research protocol and sign a Data Access Agreement with the principal investigator to ensure participant privacy and data security.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- ANALYTIC_CODE
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .